207 related articles for article (PubMed ID: 17657799)
1. Concurrent chemoradiotherapy with weekly paclitaxel and carboplatin for locally advanced head and neck cancer: Long-term follow-up of a Brown University Oncology Group Phase II Study (HN-53).
Chougule PB; Akhtar MS; Rathore R; Koness J; McRae R; Nigri P; Radie-Keane K; Kennedy T; Wanebo HJ; Ready N
Head Neck; 2008 Mar; 30(3):289-96. PubMed ID: 17657799
[TBL] [Abstract][Full Text] [Related]
2. Concurrent paclitaxel, carboplatin, and radiotherapy in advanced head and neck cancers: a phase II study--preliminary results.
Chougule P; Wanebo H; Akerley W; McRae R; Nigri P; Leone L; Safran H; Ready N; Koness RJ; Radie-Keane K; Cole B
Semin Oncol; 1997 Dec; 24(6 Suppl 19):S19-57-S19-61. PubMed ID: 9427268
[TBL] [Abstract][Full Text] [Related]
3. The evaluation of amifostine for mucosal protection in patients with advanced loco-regional squamous cell carcinomas of the head and neck (SCCHN) treated with concurrent weekly carboplatin, paclitaxel, and daily radiotherapy (RT).
Suntharalingam M; Jaboin J; Taylor R; Wolf J; Banglore M; Van Echo D; Ord R
Semin Oncol; 2004 Dec; 31(6 Suppl 18):2-7. PubMed ID: 15726515
[TBL] [Abstract][Full Text] [Related]
4. Chemoradiotherapy for advanced inoperable head and neck cancer: A phase II study.
Chougule PB; Akhtar MS; Akerley W; Ready N; Safran H; McRae R; Nigri P; Bellino J; Koness J; Radie-Keane K; Wanebo H
Semin Radiat Oncol; 1999 Apr; 9(2 Suppl 1):58-63. PubMed ID: 10210541
[TBL] [Abstract][Full Text] [Related]
5. Randomized phase 2 study of concomitant chemoradiotherapy using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with locally advanced head and neck cancer.
Haddad R; Sonis S; Posner M; Wirth L; Costello R; Braschayko P; Allen A; Mahadevan A; Flynn J; Burke E; Li Y; Tishler RB
Cancer; 2009 Oct; 115(19):4514-23. PubMed ID: 19634161
[TBL] [Abstract][Full Text] [Related]
6. Preoperative paclitaxel, carboplatin, and radiation therapy in advanced head and neck cancer (stage III and IV).
Wanebo HJ; Chougule P; Ready N; Koness RJ; Akerley W; McRae R; Nigri P; Leone L; Webber B; Safran H
Semin Radiat Oncol; 1999 Apr; 9(2 Suppl 1):77-84. PubMed ID: 10210544
[TBL] [Abstract][Full Text] [Related]
7. Induction chemotherapy followed by concomitant TFHX chemoradiotherapy with reduced dose radiation in advanced head and neck cancer.
Haraf DJ; Rosen FR; Stenson K; Argiris A; Mittal BB; Witt ME; Brockstein BE; List MA; Portugal L; Pelzer H; Weichselbaum RR; Vokes EE
Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5936-43. PubMed ID: 14676118
[TBL] [Abstract][Full Text] [Related]
8. Selective organ preservation in operable locally advanced head and neck squamous cell carcinomas guided by primary site restaging biopsy: long-term results of two sequential brown university oncology group chemoradiotherapy studies.
Wanebo HJ; Rathore R; Chougule P; DiSiena MR; Koness RJ; McRae RG; Nigri PT; Radie-Keane K; Ready N
Ann Surg Oncol; 2011 Nov; 18(12):3479-85. PubMed ID: 21553142
[TBL] [Abstract][Full Text] [Related]
9. Weekly paclitaxel and carboplatin induction chemotherapy followed by concurrent chemoradiotherapy in locally advanced squamous cell carcinoma of the head and neck.
Ready NE; Rathore R; Johnson TT; Nadeem A; Chougule P; Ruhl C; Radie-Keane K; Theall K; Wanebo HJ; Marcello J; Kennedy T
Am J Clin Oncol; 2012 Feb; 35(1):6-12. PubMed ID: 21293244
[TBL] [Abstract][Full Text] [Related]
10. Concurrent hyperfractionated radiotherapy and low-dose daily carboplatin and paclitaxel in patients with stage III non-small-cell lung cancer: long-term results of a phase II study.
Jeremic B; Milicic B; Acimovic L; Milisavljevic S
J Clin Oncol; 2005 Feb; 23(6):1144-51. PubMed ID: 15718310
[TBL] [Abstract][Full Text] [Related]
11. Taxane-based chemoirradiation for organ preservation with locally advanced head and neck cancer: results of a phase II multi-institutional trial.
Cmelak AJ; Murphy BA; Burkey B; Douglas S; Shyr Y; Netterville J
Head Neck; 2007 Apr; 29(4):315-24. PubMed ID: 17252600
[TBL] [Abstract][Full Text] [Related]
12. Intensity-modulated radiation therapy in advanced head and neck patients treated with intensive chemoradiotherapy: preliminary experience and future directions.
Milano MT; Vokes EE; Kao J; Jackson W; List MA; Stenson KM; Witt ME; Dekker A; MacCracken E; Garofalo MC; Chmura SJ; Weichselbaum RR; Haraf DJ
Int J Oncol; 2006 May; 28(5):1141-51. PubMed ID: 16596230
[TBL] [Abstract][Full Text] [Related]
13. Neck dissection in the combined-modality therapy of patients with locoregionally advanced head and neck cancer.
Argiris A; Stenson KM; Brockstein BE; Mittal BB; Pelzer H; Kies MS; Jayaram P; Portugal L; Wenig BL; Rosen FR; Haraf DJ; Vokes EE
Head Neck; 2004 May; 26(5):447-55. PubMed ID: 15122662
[TBL] [Abstract][Full Text] [Related]
14. Induction paclitaxel and carboplatin for patients with head and neck carcinoma. Analysis of 62 patients treated between 1994 an 1999.
Dunphy FR; Dunleavy TL; Harrison BR; Trinkaus KM; Kim HJ; Stack BC; Needles B; Boyd JH
Cancer; 2001 Mar; 91(5):940-8. PubMed ID: 11251945
[TBL] [Abstract][Full Text] [Related]
15. Induction chemotherapy with paclitaxel plus carboplatin followed by paclitaxel with concurrent radiotherapy in stage IIIB non-small-cell lung cancer (NSCLC) patients: a phase II trial.
Pallarés C; Capdevila J; Paredes A; Farré N; Ciria JP; Membrive I; Basterrechea L; Gomez-Segura G; Barnadas A
Lung Cancer; 2007 Nov; 58(2):238-45. PubMed ID: 17658655
[TBL] [Abstract][Full Text] [Related]
16. Toxicity and outcome analysis of patients with recurrent head and neck cancer treated with hyperfractionated split-course reirradiation and concurrent cisplatin and paclitaxel chemotherapy from two prospective phase I and II studies.
Kramer NM; Horwitz EM; Cheng J; Ridge JA; Feigenberg SJ; Cohen RB; Nicolaou N; Sherman EJ; Babb JS; Damsker JA; Langer CJ
Head Neck; 2005 May; 27(5):406-14. PubMed ID: 15719391
[TBL] [Abstract][Full Text] [Related]
17. Low-dose weekly platinum-based chemoradiation for advanced head and neck cancer.
Watkins JM; Zauls AJ; Wahlquist AH; Shirai K; Garrett-Mayer E; Gillespie MB; Day TA; Sharma AK
Laryngoscope; 2010 Feb; 120(2):236-42. PubMed ID: 19950378
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of palifermin and concurrent chemoradiation in head and neck squamous cell carcinoma.
Brizel DM; Murphy BA; Rosenthal DI; Pandya KJ; Glück S; Brizel HE; Meredith RF; Berger D; Chen MG; Mendenhall W
J Clin Oncol; 2008 May; 26(15):2489-96. PubMed ID: 18487568
[TBL] [Abstract][Full Text] [Related]
19. Low-dose fractionated radiation as a chemopotentiator of neoadjuvant paclitaxel and carboplatin for locally advanced squamous cell carcinoma of the head and neck: results of a new treatment paradigm.
Arnold SM; Regine WF; Ahmed MM; Valentino J; Spring P; Kudrimoti M; Kenady D; Desimone P; Mohiuddin M
Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1411-7. PubMed ID: 15050317
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of paclitaxel and carboplatin as a regimen for postoperative concurrent chemoradiotherapy of high risk uterine cervix cancer.
Kim K; Chie EK; Wu HG; Ha SW; Kim JS; Kim IA; Lee HP
Gynecol Oncol; 2006 Jun; 101(3):398-402. PubMed ID: 16330087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
